ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease

Atherosclerosis Supplements

Volumn 4, Issue 4, 2003, Pages 23-28

  Böger, Rainer H ^a   Zoccali, Carmine ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CNR   (Italy)

Author keywords

Dimethylamine diaminohydrolase; Endothelium; L Arginine; Nitric oxide; Prognosis

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; HUMAN; MORTALITY; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 1242273853     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(03)00030-8     Document Type: Article

References (26)

1. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet. 339:1992;572-575.
2. Böger R.H., Sydow K., Borlak J., Thum T., Lenzen H., Schubert B.et al. LDL Cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 87:2000;99-105.
3. MacAllister R.J., Rambausek M.H., Vallance P., Williams D., Hoffmann K.H., Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol. Dial. Transplant. 11:1996;2449-2452.
4. Anderstam B., Katzarski K., Bergstrom J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J. Am. Soc. Nephrol. 8:1997;1437-1442.
5. Kielstein J.T., Böger R.H., Bode-Böger S.M., Frölich J.C., Haller H., Böger R.H. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 10:1999;594-600.
6. G-dimethylarginine in renal insufficiency. Eur. J. Physiol. 439:2000;524-531.
7. Fleck C., Janz A., Schweitzer F., karge E., Schwertfeger M., Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int. 59(Suppl. 78):2001;S14-S18.
8. Wahbi N., Dalton R.N., Turner C., Denton M., Abbs I., Swaminathan R. Dimethylarginines in chronic renal failure. J. Clin. Pathol. 54:2001;470-473.
9. Kielstein J.T., Böger R.H., Bode-Böger S.M., Frölich J.C., Haller H., Ritz E.et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 13:2002;170-176.
10. Böger R.H., Bode-Böger S.M., Szuba A., Tangphao O., Tsao P.S., Chan J.R.et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 98:1998;1842-1847.
11. Vallance P. Importance of asymmetric dimethylarginine in cardiovascular risk. Lancet. 358:2001;2096-2097.
12. Levey A.S. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am. J. Kidney Dis. 32(Suppl. 3):1998;S5-S13.
13. Zoccali C. Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? Nephrol. Dial. Transplant. 15:2000;454-456.
14. Kari J.A., Donald A.E., Vallance D.T., Bruckdorfer K.R., Leone A., Mullen M.J.et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 52:1997;468-472.
15. Hand M.F., Haynes W.G., Webb D.J. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int. 53:1998;1068-1077.
16. Hodis H.N., Mack W.J., LaBree L., Selzer R.H., Liu C.R.et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128:1998;262-269.
17. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfs S.K. Jr.et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Project. N. Engl. J. Med. 340:1999;14-22.
18. Benedetto F.A., Mallamaci F., Tripepi G., Zoccali C. Prognostic impact of ultrasonography measurement of carotid intima media thickness in dialysis patients. J. Am. Soc. Nephrol. 12:2001;2458-2464.
19. Zoccali C., Benedetto F.A., Maas R., Mallamaci F., Tripepi G., Malatino L.et al. Asymmetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13:2002;490-496.
20. Zoccali C., Bode-Böger S.M., Mallamaci F., Benedetto F.A., Tripepi G., Malatino L.et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet. 358:2001;2113-2117.
21. Chan J.R., Böger R.H., Bode-Böger S.M., Tangphao O., Tsao P.S., Blaschke T.F.et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler. Thromb. Vasc. Biol. 20:2000;1040-1046.
22. Rector T.S., Bank A.J., Mullen K.A., Tschumperlin L.K., Sih R., Pillai K.et al. Randomized, double-blind, placebo-controlled study of supplental oral L-arginine in patients with heart failure. Circulation. 93:1996;2135-2141.
23. Ceremuczynski L., Chamiec T., Herbacynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am. J. Cardiol. 80:1997;331-333.
24. Böger R.H., Bode-Böger S.M., Thiele W., Creutzig A., Alexander K., Frölich J.C. Restoring vascular NO formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol. 32:1998;1336-1344.
25. Maxwell A.J., Anderson B.E., Cooke J.P. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc. Med. 5:2000;11-19.
26. Tsikas D., Böger R.H., Sandmann J., Bode-Böger S.M., Frölich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett. 23810:2000;1-3.